Published in Oncol Rep on October 01, 2004
Prognostic molecular markers with no impact on decision-making: the paradox of gliomas based on a prospective study. Br J Cancer (2008) 1.01
rs4919510 in hsa-mir-608 is associated with outcome but not risk of colorectal cancer. PLoS One (2012) 0.98
Alterations of BCCIP, a BRCA2 interacting protein, in astrocytomas. BMC Cancer (2009) 0.95
Detailed characterization of alterations of chromosomes 7, 9, and 10 in glioblastomas as assessed by single-nucleotide polymorphism arrays. J Mol Diagn (2011) 0.85
Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med (2007) 5.87
Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res (2006) 4.72
A CD36-initiated signaling cascade mediates inflammatory effects of beta-amyloid. J Biol Chem (2002) 2.85
CD36 mediates the innate host response to beta-amyloid. J Exp Med (2003) 2.65
Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer (2003) 2.01
Overheated and melted intracranial pressure transducer as cause of thermal brain injury during magnetic resonance imaging: case report. J Neurosurg (2012) 1.99
Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. Clin Cancer Res (2006) 1.91
Mesenchymal stem cells that produce neurotrophic factors reduce ischemic damage in the rat middle cerebral artery occlusion model. Mol Ther (2005) 1.91
BDNF gene-modified mesenchymal stem cells promote functional recovery and reduce infarct size in the rat middle cerebral artery occlusion model. Mol Ther (2004) 1.87
A simple and useful coma scale for patients with neurologic emergencies: the Emergency Coma Scale. Am J Emerg Med (2010) 1.53
De novo formation and rupture of an aneurysm. Case report. J Neurosurg (2002) 1.52
MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. Int J Cancer (2009) 1.48
Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. Cancer Res (2002) 1.48
Correlation of L-methyl-11C-methionine (MET) uptake with L-type amino acid transporter 1 in human gliomas. J Neurooncol (2010) 1.48
Aberrant promoter methylation of human DAB2 interactive protein (hDAB2IP) gene in lung cancers. Int J Cancer (2005) 1.45
Enhanced brain angiogenesis in chronic cerebral hypoperfusion after administration of plasmid human vascular endothelial growth factor in combination with indirect vasoreconstructive surgery. J Neurosurg (2005) 1.44
Assessment of the difference in posterior circulation involvement between pediatric and adult patients with moyamoya disease. J Neurosurg (2013) 1.42
Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in breast cancer. Clin Cancer Res (2004) 1.39
Significant correlation of the SCN1A mutations and severe myoclonic epilepsy in infancy. Biochem Biophys Res Commun (2002) 1.37
Reduced expression of the REIC/Dkk-3 gene by promoter-hypermethylation in human tumor cells. Gene (2002) 1.34
Exercise exerts neuroprotective effects on Parkinson's disease model of rats. Brain Res (2009) 1.33
Angiogenesis and invasion in glioma. Brain Tumor Pathol (2011) 1.31
Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson's disease. Eur J Neurosci (2004) 1.30
Liposomal delivery of MicroRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells. Mol Cancer Ther (2011) 1.29
Anti-high mobility group box-1 monoclonal antibody protects the blood-brain barrier from ischemia-induced disruption in rats. Stroke (2011) 1.26
Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma. Cancer (2003) 1.23
11C-methionine (MET) and 18F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma. Eur J Nucl Med Mol Imaging (2008) 1.20
Expression and mutation analysis of epidermal growth factor receptor in head and neck squamous cell carcinoma. Cancer Sci (2008) 1.19
The NH2 terminus of influenza virus hemagglutinin-2 subunit peptides enhances the antitumor potency of polyarginine-mediated p53 protein transduction. J Biol Chem (2004) 1.19
Allelic loss and reduced expression of the ING3, a candidate tumor suppressor gene at 7q31, in human head and neck cancers. Oncogene (2002) 1.19
Establishment and characterization of a biphasic synovial sarcoma cell line, SYO-1. Cancer Lett (2004) 1.18
Frequent deletion and down-regulation of ING4, a candidate tumor suppressor gene at 12p13, in head and neck squamous cell carcinomas. Gene (2005) 1.18
Edaravone attenuates brain edema and neurologic deficits in a rat model of acute intracerebral hemorrhage. Stroke (2007) 1.16
E prostanoid 2 (EP2)/EP4-mediated suppression of antigen-specific human T-cell responses by prostaglandin E2. Immunology (2006) 1.13
Intravenous administration of mesenchymal stem cells exerts therapeutic effects on parkinsonian model of rats: focusing on neuroprotective effects of stromal cell-derived factor-1alpha. BMC Neurosci (2010) 1.11
Differences in the neuronal stem cells survival, neuronal differentiation and neurological improvement after transplantation of neural stem cells between mild and severe experimental traumatic brain injury. J Med Invest (2006) 1.11
The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. Int J Cancer (2007) 1.09
Intravenous route of cell delivery for treatment of neurological disorders: a meta-analysis of preclinical results. Stem Cells Dev (2010) 1.09
Anti-high mobility group box-1 antibody therapy for traumatic brain injury. Ann Neurol (2012) 1.08
In vivo animal stroke models: a rationale for rodent and non-human primate models. Transl Stroke Res (2013) 1.07
Multi-step aberrant CpG island hyper-methylation is associated with the progression of adult T-cell leukemia/lymphoma. Am J Pathol (2009) 1.06
EGFR mutation status in pleural fluid predicts tumor responsiveness and resistance to gefitinib. Lung Cancer (2007) 1.05
Intravenous grafts of amniotic fluid-derived stem cells induce endogenous cell proliferation and attenuate behavioral deficits in ischemic stroke rats. PLoS One (2012) 1.05
Isolation and transplantation of dopaminergic neurons generated from mouse embryonic stem cells. Neurosci Lett (2004) 1.04
Embryonic neural stem cells transplanted in middle cerebral artery occlusion model of rats demonstrated potent therapeutic effects, compared to adult neural stem cells. Brain Res (2008) 1.04
Loss or down-regulation of HLA class I expression at the allelic level in freshly isolated leukemic blasts. Cancer Sci (2007) 1.04
The relationship between peritumoral brain edema and the expression of vascular endothelial growth factor and its receptors in intracranial meningiomas. J Neurooncol (2004) 1.03
Production of aromatic compounds by metabolically engineered Escherichia coli with an expanded shikimate pathway. Appl Environ Microbiol (2012) 1.03
MRI of transgene expression: correlation to therapeutic gene expression. Neoplasia (2002) 1.03
CYP2C polymorphisms, phenytoin metabolism and gingival overgrowth in epileptic subjects. Life Sci (2004) 1.03
Tumor-specific mutation and downregulation of ING5 detected in oral squamous cell carcinoma. Int J Cancer (2010) 1.02
Downregulation of TESTIN and its association with cancer history and a tendency toward poor survival in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg (2009) 1.02
Laparoscopic-assisted resection of gastrointestinal stromal tumor in small intestine. Hepatogastroenterology (2008) 1.02
Detection of codon 61 point mutations of the K-ras gene in lung and colorectal cancers by enriched PCR. Oncol Rep (2003) 1.01
Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo. Cancer Lett (2004) 1.01
Genome-wide analyses on loss of heterozygosity in head and neck squamous cell carcinomas. Lab Invest (2003) 1.00
Prevalent hyper-methylation of the CDH13 gene promoter in malignant B cell lymphomas. Int J Oncol (2004) 1.00
Fine deletion mapping of chromosome 2q21-37 shows three preferentially deleted regions in oral cancer. Oral Oncol (2006) 1.00
Genetic and epigenetic alterations of BRG1 promote oral cancer development. Int J Oncol (2005) 0.99
Potent synergy of dual antitumor peptides for growth suppression of human glioblastoma cell lines. Mol Cancer Ther (2008) 0.99
Seizure suppression in amygdala-kindled mice by transplantation of neural stem/progenitor cells derived from mouse embryonic stem cells. Neurol Med Chir (Tokyo) (2010) 0.99
Large supratentorial ectopic ependymoma with massive calcification and cyst formation--case report. Neurol Med Chir (Tokyo) (2004) 0.99
Accumulation of aberrant CpG hypermethylation by Helicobacter pylori infection promotes development and progression of gastric MALT lymphoma. Int J Oncol (2009) 0.98
Neuroprotective effects of edaravone-administration on 6-OHDA-treated dopaminergic neurons. BMC Neurosci (2008) 0.98
Detection of seizure-associated high-frequency oscillations above 500Hz. Epilepsy Res (2009) 0.98
Heparanase is involved in angiogenesis in esophageal cancer through induction of cyclooxygenase-2. Clin Cancer Res (2005) 0.97
Decreased expression of the SIN3A gene, a candidate tumor suppressor located at the prevalent allelic loss region 15q23 in non-small cell lung cancer. Lung Cancer (2007) 0.97